載入...
Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status
BACKGROUND: While reduction of accumulated body fluid using loop diuretics is a commonly used therapeutic option for acute heart failure (AHF), some patients, especially those with chronic kidney disease (CKD), show significantly poor treatment response to loop diuretics. Tolvaptan (TLV) has shown e...
Na minha lista:
| 發表在: | J Clin Med Res |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Elmer Press
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6306139/ https://ncbi.nlm.nih.gov/pubmed/30627278 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3671 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|